Common use of Terms Defined Elsewhere Clause in Contracts

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(b) Agreement Preamble Antitrust Approvals 4.3(b) Applicable Cap Amount 6.5(b)(i) Assigned Contracts 1.1(a)(iii) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) ▇▇▇▇ of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee 9.3(a) Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Closing 1.3(a) Closing Date 1.3(a) Closing Net Working Capital 1.4(a) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b) Confidentiality Agreement 4.2 Contingent Payment 1.2(b) CTAs 2.9(b) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) Excluded Assets 1.1(b) Excluded Liabilities 1.1(d) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(b) Material Contract 2.10(a) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(a) Non-Compete Period 9.9(a) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(i) Outside Date 7.1(d)(ii) Parties Preamble Party Preamble Patent Assignment Agreement 1.3(b)(v) Permits 1.1(a)(iv) Pre-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(a) Straddle Period 8.1(b)(i) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Party Claim 6.3(a) Third Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(vii) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(ii)

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: 2017 Bonuses 9.3(a280G Stockholder Approval 6.6(b) Acquired Assets 1.1(aAdjustment Resolution Period 2.9(b) Aggregate Threshold 6.5(b)(iiAdjustment Review Period 2.9(b) Agreed Amount 6.3(bAdvisory Committee 8.6(b) Agreement Preamble Antitrust Approvals 4.3(bAgreement Date Preamble Agreement Date Committed Equity Individual 3.2(e) Applicable Cap Amount 6.5(b)(iAllocation Schedule 5.3(a) Assigned Contracts 1.1(a)(iiiAnti-Corruption Laws 3.24 Audited Financials 3.7(a) Assumed Liabilities 1.1(cAutomatic Resale Registration Statement 5.6(b) Assumption Agreements 1.1(c) ▇▇▇▇ of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee 9.3(a) Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Closing 1.3(a) Closing Date 1.3(a) Closing Net Working Capital 1.4(a) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b3.7(b) Behavioral Data 3.12(a)(i) Board Recitals Books and Records 3.17(b) Cancelled Options 2.1(b)(iii) Cancelled RSU 2.1(b)(vii) Cancelled Shares 2.1(f) CASL 3.12(a)(xv) CCPA 3.12(a)(xv) Certificate of Incorporation 3.1(d) Charter Documents 3.1(d) Closing 1.4 Closing Date 1.4 Company Preamble Company Authorizations 3.15 Company Board Resolutions 3.4(a) Company Certificate 7.2(c) Company Data 3.12(a)(iii) Company Group 10.14 Company Indemnitees 5.5(a) Company IP 3.12(a)(v) Company Owned IP 3.12(a)(v) Company Prepared Returns 5.2(a)(i) Company Privacy Policy 3.12(a)(vi) Company Products 3.12(a)(vii) Company Products Data 3.12(a)(viii) Company Registered IP 3.12(b) Company Software 3.12(a)(ix) Company Source Code 3.12(a)(x) Company Stockholder Approval Recitals Company Systems 3.12(q)(i) Company Voting Debt 3.2(f) Confidentiality Agreement 4.2 Contingent Payment 1.2(b6.7 Contaminants 3.12(a)(xi) CTAs 2.9(bConverted Option 2.1(b)(ii) Damages 6.1 DOJ 4.3(aConverted Option Exercise Price 2.1(b)(ii) Domain Name Assignment Converted RSU 2.1(b)(v) CRTC 3.12(q)(v) Current Balance Sheet 3.7(b) Cyber Tail Policy 5.5(b) D&O Indemnifiable Matters 5.5(a) D&O Tail Policy 5.5(b) Deductible Amount 8.3(a) Determination Date 2.9(c) DGCL 1.1 Director and Officer Resignation Letters 1.5(a)(iv) Disclosure Schedule Article III Dissenting Shares 2.5(a) DLLCA 1.1 Effective Time 1.2 Embargoed Countries 3.23 End Date 9.1(b) Enforcement Exceptions 3.4(a) Engagement Letter 8.6(b) ePrivacy Directive 3.12(a)(xv) Escrow Agreement 1.3(b)(vi1.5(a)(ix) Downward Estimated Closing Cash Amount 2.9(a) Estimated Closing Indebtedness Amount 2.9(a) Estimated Closing Statement 2.9(a) Estimated Closing Third-Party Expenses 2.9(a) Estimated Closing Working Capital Adjustment Amount 1.4(c)(i2.9(a) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(aExchange Documents 2.3(b) Employment Practices 2.15(bExpense Fund 8.6(c) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(aExpense Fund Account 8.6(c) Estimated Net Working Capital 1.2(e) Excluded Assets 1.1(b) Excluded Liabilities 1.1(d) FDA 2.13(bExport Approvals 3.23 FCPA 3.24 Final Closing Statement 2.9(c) Final Allocation 8.5 Final Net Working Capital 1.4(b)(ivSurviving Entity 1.1 Financials 3.7(a) FSA Balances 9.3(aFirm 10.14 FIRPTA Compliance Certificate 1.5(a)(viii) FSA Participants 9.3(aFirst Certificate of Merger 1.2 First Merger Recitals First Step Surviving Corporation 1.1 Fund Transferee 5.4(c) FTC 4.3(aGDPR 3.12(a)(xv) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(aHIPAA 3.12(a)(xv) HSR Act 2.4(b6.9(b) Identified Stockholders Recitals Inbound Licenses 3.12(d)(i) Indemnification Claim Notice 8.4(a) Indemnification Claim Objection Notice 8.4(b) Indemnified Person 5.6(f) Independent Accountant 2.9(b) Intellectual Property Rights 3.12(a)(xii) Interested Party 6.3(a3.14(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(ivInterim Financials 3.7(a) Lease 2.8(bAgreements 3.11(b) Leased Real Property 2.8(b3.11(b) Letter of Transmittal 2.3(a) Material Contract 2.10(a3.13(b) Material Customers 2.11 Contracts 3.13(b) Merger Recitals Merger Sub I Preamble Merger Sub II Preamble Merger Subs Preamble Notice of Adjustment Disagreement 2.9(b) OFAC 3.23 Open Source Licenses 3.12(a)(xiii) Open Source Material Suppliers 2.11 New Buyer Employee 9.3(a3.12(a)(xiii) Non-Compete Period 9.9(aOpen Trading Window 5.6(b) Non-Contingent Bonuses 9.3(cOther Indemnity Claim 8.3(c) Non-Solicit Period 9.9(bOther Indemnity Continuing Claim 8.4(e) Objection Notice 1.4(b)(iOther Indemnity Retained Escrow Amount 8.4(e) Outside Date 7.1(d)(iiOutbound Licenses 3.12(d)(ii) Parachute Payment Waiver 6.6(a) Parent Preamble Parent Board Approval 4.2 Parent Certificate 7.3(f) Parent Financial Statements 4.5(b) Parent Indemnified Parties Preamble Party Preamble 8.2(a) Parent Prepared Returns 5.2(a)(ii) Parent SEC Documents 4.5(a) Parent Stock Issuance Recitals Patent Assignment Rights 3.12(a)(xii) Paying Agent Agreement 1.3(b)(v2.3(a) Permits 1.1(a)(ivPayoff Letter 1.5(a)(vi) PrePermitted Suspension 5.6(e) Permitted Transferee 5.4(c) Personal Data 3.12(a)(xiv) Personnel Agreements 3.12(f)(i) PIPEDA 3.12(a)(xv) Post-Closing Period 4.1(aDeficit Amount 2.9(d) Post-Closing Excess Amount 2.9(e) Post-Closing Statement 2.9(b) Post-Signing Committed Equity Individual 6.1(e) Privacy Requirements 3.12(a)(xv) Process 3.12(a)(xvi) Processing 3.12(a)(xvi) Prohibited Party Lists 3.23 PTO 3.12(b) Registered Business IP 2.9(a3.12(a)(xvii) Regulatory Authority 2.13(bRegistrable Shares 5.6(a) Regulatory Filings 4.3(aRegistration Deadline 5.6(b) Reimbursement Amount 9.4(cRegistration Period 5.6(b) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(dRepresentative Losses 8.6(b) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(aRequired Information 2.3(a) Seller Disclosure Letter Article II Seller FDA Letters 5.2(gResale Registration Statement 5.6(a) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(a) Straddle Period 8.1(b)(i) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Party Claim 6.3(a) Third Party IP Resolved Matters 2.9(b) Trademark Assignment Restricted Shares 3.2(a) Rev. Proc. 2018-12 5.2(d)(ii) RSU Agreement 1.3(b)(vii6.18 RW Indemnity Continuing Claim 8.4(e) Transfer Taxes 8.1(aRW Indemnity Retained Escrow Amount 8.4(e) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(ii)Second Certificate of Merger 1.2 Second Effective Time 1.2

Terms Defined Elsewhere. The following is a list of additional terms are defined elsewhere used in this Agreement, as indicated belowAgreement and a reference to the Section hereof in which such term is defined: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(bAcquisition Sub Preamble Acquisition Sub Company Common Stock 2.8(c) Agreement Preamble Antitrust Approvals Laws 5.5 Certificates 2.10(b) Closing 2.3(a) Closing Adjustment 2.14(b) Closing Cash 2.14(a) Closing Cash Target 2.14(a) Closing Consideration Allocation Schedule 2.9(c) Closing Date 2.3(a) COBRA Coverage 3.12(e) Collective Bargaining Agreement 3.17(a) Company Preamble Company Assets 3.5 Company Bylaws 2.3(c)(ii) Company Disclosure Schedule Article III: Preamble Company-Owned Intellectual Property 3.18(a) Company Stockholder Approval 3.3(b) Company Warrants 3.4(c) Confidentiality Agreement 5.4(d) Copyrights 3.18(a) DGCL 4.3(a) Dissenting Shares 2.12 DOJ 5.5(b) Early Termination Election 7.1(c) Early Termination Override Notice 7.1(c) Effective Time 2.2 Employee Plans 3.12(a) Employment Agreements 2.3(b)(iv) Estimated Closing Cash 2.14(b) Exchange Act 4.5(a) FCPA 3.25(a) FTC 5.5(b) General Enforceability Exceptions 3.3(a) In-Bound License Agreements 3.6(a)(v) Indemnified Officers 5.7(a) Infringes 3.18(d) Insurance 3.19 Intellectual Property 3.18(a) Letter of Transmittal 2.10(b) License Agreement 3.6(a)(v) Material Contracts 3.6(a) Merger 2.1 Merger Certificate 2.2 Money Laundering Laws 3.25(b) Multi-Employer Plan 3.12(a) Non-Union Employees 5.8(a) NRS 2.1 Out-Bound License Agreements 3.6(a)(v) Outside Date 7.1(b) Parent Preamble Parent SEC Documents 4.5(a) Parent Stockholder Approval 4.3(b) Applicable Cap Amount 6.5(b)(iParty Representative 5.2(a) Assigned Contracts 1.1(a)(iiiPatents 3.18(a) Assumed Liabilities 1.1(cPayoff Letter 2.9(b) Assumption Agreements 1.1(cPre-Closing Taxes 3.10(a) Real Property Leases 3.7(a) Real Property Permits 3.7(g) Record Retention Period 5.12 Representative Preamble Requested Information 5.4(b) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ of Sale 1.3(b)(iiiAct 4.5(a) Business Benefit Plans 2.16(aSEC 4.5(a) Business Employee 9.3(aSecurities Act 4.5(a) Buyer Preamble Buyer FDA Letters 5.3(dSettlement Accountants 2.13(e) Buyer Group 1.1(aSoftware 3.18(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(aSpecial Meeting 5.3(e) Claim Notice 6.3(bStock Plan 3.4(b) Claimed Amount 6.3(b) Closing 1.3(a) Closing Date 1.3(a) Closing Net Working Capital 1.4(a) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b) Confidentiality Agreement 4.2 Contingent Payment 1.2(b) CTAs 2.9(b) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) Excluded Assets 1.1(b) Excluded Liabilities 1.1(d) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(b) Material Contract 2.10(a) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(a) Non-Compete Period 9.9(a) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(i) Outside Date 7.1(d)(ii) Parties Preamble Party Preamble Patent Assignment Agreement 1.3(b)(v) Permits 1.1(a)(iv) Pre-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(a) Straddle Period 8.1(b)(i) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Party Claim 6.3(aSurviving Corporation 2.1 Systems 3.18(o) Third Party IP 2.9(bIntellectual Property 3.18(b) Trademark Assignment Agreement 1.3(b)(viiTrade Secrets 3.18(a) Transfer Taxes 8.1(aTrademarks 3.18(a) Transferred Accounts Receivable 1.1(a)(xivTransaction Fee Statement 2.9(a) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(iiWARN Act Laws 3.17(d)

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(bAction 3.5(g) Agreement Preamble Antitrust Allocation Methodology 2.9(a) Allocation 2.9(b) Approvals 4.3(b2.10(a) Applicable Cap Amount 6.5(b)(i) Assigned Contracts 1.1(a)(iii) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) Asset Purchase Recitals Assignment Agreement and ▇▇▇▇ of Sale 1.3(b)(iii2.8(a)(v) Assumed Liabilities 2.6 Bankruptcy Code 2.13(h) Basket 7.6(a) Business Benefit Plans 2.16(aContracts 2.4(a) Business Employee 9.3(aCovered Person 5.9 Business Litigation Controlling Party 5.6(b) Buyer Preamble Buyer FDA Letters 5.3(dBusiness Litigation 5.6(a) Buyer Group 1.1(aBusiness Permits (b) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(aCap 7.6(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Closing 1.3(a7.4(c) Closing Date 1.3(a) 2.3 Closing Net Working Capital 1.4(a) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b2.3 Consent 5.12(a) Confidentiality Agreement 4.2 Contingent Payment 1.2(b5.2(a) CTAs 2.9(bControlling Party 7.4(b)(iii) Damages 6.1 DOJ 4.3(aCovered Activities 3.10(c) Domain Name Assignment Agreement 1.3(b)(viCovered Protected Information 3.10(c) Downward Adjustment Amount 1.4(c)(iDx Copyright License 2.13(a)(iii) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(aDx Framework Source Code 2.13(a)(iii) Employment Practices 2.15(bDx Infringement 2.13(f)(iv) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(aDx System License 2.13(a)(ii) Estimated Net Working Capital 1.2(eDx Test License 2.13(a)(i) Enforceability Limitations 3.2(b) Excluded Assets 1.1(b2.5 Expiration Date 7.1(a) Excluded Liabilities 1.1(dForeign Closing Documents 2.8(a)(vi) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a3.5(g) HSR Act 2.4(bHIPAA 3.5(g) Historical Financial Statements 7.4(a) Indemnified Party 6.3(a7.4(a) Indemnifying Party 6.3(a7.4(a) Inquiry 4.7(aIndependent Accounting Firm 2.9(b) IP Assignment Agreements 1.3(b)(viiContracts 3.9(i) IP Liability Assumption 7.4(b)(i) License Recitals Material Customer Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(b3.12(a) Material Contract 2.10(aCustomer Agreement 3.13(a) Material Customers 2.11 Customer 3.12(a) Material Suppliers 2.11 New Buyer Employee 9.3(aDistributor or Reseller Agreement 3.13(c) Material Distributor 3.13(c) Milestone Payment Date 2.2(c)(i) Milestone Payment 2.2(b)(i) Milestone Trigger 2.2(b)(i) Mutual Transfer Agreement 5.4(c) NanoString Board of Directors 3.2(a) NanoString Indemnified Parties 7.3 NanoString Indemnified Party 7.3 NanoString Other Systems 2.13(a) NanoString Preamble NIH Assignment 5.10 NIH License 5.10 NIH Outside Date 5.10 Non-Controlling Party 7.4(b)(iii) Non-Compete Period 9.9(aPaying Party 6.3(b) Non-Contingent Bonuses 9.3(cRegulatory Approvals 2.10(b) Non-Solicit Period 9.9(bTransferable Asset 2.10(a) Notice of Objection Notice 1.4(b)(i) Outside Date 7.1(d)(ii7.4(d) Parties Preamble Party Preamble Patent Assignment Agreement 1.3(b)(vPEO 5.4(c) Permits 1.1(a)(ivProduct Licenses 3.5(c) Pre-Closing Period 4.1(aPurchased Assets 2.4 Purchaser’s Allocation Notice 2.9(b) Purchaser’s Allocation 2.9(b) Registered Business IP 2.9(aLicensed Intellectual Property 3.9(a) Regulatory Authority 2.13(bPermits 5.1(a) Regulatory Filings 4.3(aRelevant Matters 8.8(a) Reimbursement Amount 9.4(cReplaced Distributor Contracts 2.10(b) Related Agreements 2.3 Restricted Names 9.5 Safety Notice Replaced Distributor Relationship 2.10(b) Replacement Distributor Contracts 2.10(b) Replacement NIH License Agreement 5.10 Retained Liabilities 2.7 Review Committee 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(aStockholders 3.2(a) Straddle Period 8.1(b)(iTax 6.3(b) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Third-Party Claim 6.3(aNotice 7.4(a) Third Third-Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(viiClaim 7.4 Transactions Recitals Transfer Claimant 5.4(d) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi6.3(a) Transferred Permits 1.1(a)(iv2.4(d) Transition Services Agreement 1.3(b)(xPeriod 2.10(b) Upfront Payment 1.2(aUnilateral Settlement 7.4(b)(iii) Upward Adjustment Amount 1.4(c)(ii)Universal Panel 2.13(a) Update Report 2.2(c)(ii) Veracyte Indemnified Parties 7.2 Veracyte Indemnified Party 7.2 Veracyte SEC Documents 4.6(a) Veracyte Preamble

Terms Defined Elsewhere. The following terms are defined elsewhere in the following sections of this Agreement, as indicated below: 2017 Bonuses 9.3(aAcquisition Proposal 4.2(b) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(b) Affiliate 9.2 Agreement Preamble Antitrust Approvals 4.3(bAggrieved Party 7.2(a) Applicable Cap Amount 6.5(b)(iALLL 3.16(a) Assigned Contracts 1.1(a)(iii) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) ▇▇▇▇ of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee 9.3(a) Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Closing 1.3(a) Closing Date 1.3(a) Closing Net Working Capital 1.4(a) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b3.8(a) Confidentiality Bank Merger Preamble Bank Merger Effective Time 1.4(a) Bank Regulations 1.1 Bank Regulators 9.2 Breaching Party 7.2(a) Certificates 1.3(c)(i) CGLC 1.1(a) Change of Control Benefit 3.17(e) Closing 1.5 Closing Date 1.5 Closing Financial Statements 4.8 Code 3.13(b) Company Preamble Company Bank Preamble Company Bank Common Stock 1.4(a) Company Common Stock 1.3(b) Company Entities Premises 3.18(b) Company Real Property 3.20(c) Company SEC Reports 3.9(b) Company Shareholders’ Meeting 4.3 Company Stock Option Plan 3.6(b) Company Stock Options 3.6(b) Company Bank Regulatory Agreement 4.2 Contingent Payment 1.2(b3.22(b) CTAs 2.9(bCRA 2.7(c) Damages 6.1 DOJ 4.3(aDerivative Instruments 3.19(e)(iv) Domain Name Assignment Agreement 1.3(b)(viDetermination Date 4.8 Dissenting Shares 1.3(b) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Effective Time 1.2 Encumbrance 9.2 Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a9.2 Exchange Agent 1.3(c)(i) Estimated Net Working Capital 1.2(e) Excluded Assets 1.1(b) Excluded Liabilities 1.1(d) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(aExchange Act 3.4(a) (a) Governmental Entity 2.4(b2.4(a) (a) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(bKnowledge 9.2 Law 3.4(b) Material Adverse Effect 9.2 Material Contract 2.10(a3.19(a) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(aMerger Preamble Merger Agreement 1.2 Merger Consideration 1.3(a)(i) Non-Compete Period 9.9(aMerger Consideration Adjustment 1.3(c)(ii) Non-Contingent Bonuses 9.3(cParent Preamble Parent’s Agents 5.11 Parent SEC Reports 2.6(a) Non-Solicit Period 9.9(bPermitted Encumbrances 3.20(a) Objection Notice 1.4(b)(iPer Share Merger Consideration 1.3(c)(ii) Outside Date 7.1(d)(iiPerson 9.2 Preferred Share Purchase Rights 3.6(b) Parties Preamble Party Preamble Patent Assignment Required Regulatory Approvals 3.25 Rights Plan 3.6(b) Securities Act 3.5 Shareholder Agreement 1.3(b)(v6.2(e) Permits 1.1(a)(iv) Pre-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(a) Straddle Period 8.1(b)(i) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Party Claim 6.3(a) Third Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(vii) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(ii)Subsidiary 9.2

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: 2017 Bonuses 9.3(aAgent 3.2(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(bAgent Agreement 3.2(a) Agreement Preamble Antitrust Approvals 4.3(bLaws 8.2(b) Applicable Cap Amount 6.5(b)(iAudited Driveline Financial Statements 8.12(a) Assigned Contracts 1.1(a)(iiiBase Premium 8.4(d) Assumed Liabilities 1.1(cCertificate 3.2(b)(ii) Assumption Agreements 1.1(cCertificate of Merger 2.3 Closing 2.2 Closing Date 2.2 Covered Persons 8.4(a) ▇▇▇▇ of Sale 1.3(b)(iiiPreamble ▇▇▇▇ Board Recitals ▇▇▇▇ Board Recommendation Recitals ▇▇▇▇ Common Stock 6.2(a) Business Benefit Plans 2.16(a▇▇▇▇ Disclosure Letter VI ▇▇▇▇ Equity Interests 6.2(a) Business Employee 9.3(a▇▇▇▇ Financial Statements 6.7(b) Buyer Preamble Buyer FDA Letters 5.3(d▇▇▇▇ IP Agreements 6.16(b) Buyer Group 1.1(a▇▇▇▇ Material Contract 6.14(b) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a▇▇▇▇ Permits 6.17(b) Claim Notice 6.3(b▇▇▇▇ Preferred Stock 6.2(a) Claimed Amount 6.3(b▇▇▇▇ SEC Documents 6.7(a) Closing 1.3(a▇▇▇▇ Transaction Litigation 8.8 Debt Commitment Letter 6.24(a) Closing Date 1.3(aDivestiture Action 8.2(c) Closing Net Working Capital 1.4(aDriveline Agreements 5.9(a) Closing Statement 1.4(aDriveline IP Agreements 5.11(b) COBRA 9.3(fDriveline Material Contract 5.9(b) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(bDriveline Permit 5.12(b) Confidentiality Agreement 4.2 Contingent Payment 1.2(bEffective Time 2.3 Enforceability Exceptions 4.2(a) CTAs 2.9(b) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(eExchange Fund 3.2(a) Excluded Assets 1.1(bInformation 8.10(c)(iv) Excluded Liabilities 1.1(dFee Letter 6.23(a) FDA 2.13(bFinancing 6.23(a) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(b) Material Contract 2.10(a) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(a) Non-Compete Period 9.9(a) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(i) Outside Date 7.1(d)(ii) Parties GKN Preamble Party Preamble Patent Assignment Agreement 1.3(b)(v) Permits 1.1(a)(iv) Pre-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble Seller GKN Board 2.3 Seller Change of Recitals GKN Board Recommendation 4.7(a) Seller Recitals GKN Disclosure Letter Article II Seller FDA Letters 5.2(gIV GKN Transaction Litigation 8.8 Indemnification Agreements 8.4(a) Seller FSA 9.3(aMerger 2.1 Merger Consideration 3.1(a)(i) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(vMerger Regulation 9.1(d)(i) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(iMerger Sub Preamble Merger Sub Common Stock 3.1(b) Seller Trademarks 9.6 Shire Milestone Payment 9.4(aNYSE 4.4 Required Amount 6.23 ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act 6.7(a) Specified Milestone Payment 9.4(aSpinCo Preamble SpinCo Board 2.6(a)(i) Straddle Period 8.1(b)(iSpinCo Options 3.4(a) Sublease 1.3(b)(xiSpinCo PSUs 3.4(d) Supply Agreements 4.6 Tax Claim 8.4 Third Party Claim 6.3(aSpinCo RSUs 3.4(c) Third Party IP 2.9(bSpinCo SARs 3.4(b) Trademark Assignment Agreement 1.3(b)(vii) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(iiSurviving Corporation 2.1 Transaction Litigation 8.8 Unaudited Interim Driveline Financial Statements 8.12(b)

Terms Defined Elsewhere. The following terms are defined elsewhere As used in this Agreement, the following capitalized terms are defined in this Agreement as indicated belowreferenced in the following table: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(b) Agreement Preamble Antitrust Approvals 4.3(bBylaws 3.2 Capitalization Date 5.2(a) Applicable Cap Amount 6.5(b)(iChange of Recommendation 7.2(d)(i)(F) Assigned Contracts 1.1(a)(iii) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) ▇▇▇▇ of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee 9.3(a) Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Charter 3.1 Closing 1.3(a) 2.1 Closing Date 1.3(a2.1 Company Preamble Company Approvals 5.4(a) Closing Net Working Capital 1.4(aCompany Disclosure Letter Article V Company Personal Information 5.18(l) Closing Statement 1.4(aCompany Recommendation 5.3(b) COBRA 9.3(fCompany Tax Representation Letter 7.18(c) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(bContinuation Period 7.11(a) Confidentiality Agreement 4.2 Contingent Payment 1.2(bD&O Insurance 7.12(b) CTAs 2.9(bDelisting Period 7.17(a) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) Excluded Assets 1.1(b) Excluded Liabilities 1.1(dEffective Time 2.2 Exchange Fund 4.3(a)(i) FDA 2.13(b5.20(a) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(aFDA Licenses 5.20(a) Fundamental Representations 6.4(aAction 7.2(d)(iii) Governmental Antitrust Entity 2.4(b7.6(b)(ii) Hazardous Substances 2.19 Healthcare Laws 2.13(aInterim Period 7.1(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(bLegal Restraint 8.1(c) Material Contract 2.10(a5.11(a) Material Customers 2.11 Customer 5.12(a) Material Suppliers 2.11 New Buyer Employee 9.3(aVendor 5.12(b) Merger Recitals Merger Sub Preamble Non-Compete Wholly Owned Subsidiary 5.2(f) Notice of Redemption 7.13(a) Notice 7.2(d)(iii) Notice Period 9.9(a) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(i7.2(d)(iii) Outside Date 7.1(d)(ii9.2(a) Parent Preamble Parent Approvals 6.4(a) Parent DSU 4.2(f) Parent Option 4.2(a) Parent RSU 4.2(c) Parent Tax Representation Letter 7.18(c) Parent SAR 4.2(e) Parties Preamble Party Preamble Patent Assignment Permitted Confidentiality Agreement 1.3(b)(v) Permits 1.1(a)(iv) Pre-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(aPotential Purchasers 7.6(d) Specified Milestone Payment 9.4(aPotential Sale Transaction 7.6(d) Straddle Period 8.1(b)(iPrivacy and Security Measures 5.18(k) Sublease 1.3(b)(xiPrivacy-Related Contracts 5.11(a)(vi) Supply Agreements 4.6 Proxy Statement 7.3(a) Stock Ownership Rep 6.8 Support Agreement Recitals Surviving Corporation 2.3 Tax Claim 8.4 Third Representation Letters 7.18(c) Third-Party Claim 6.3(aConsents 7.8 Transaction Litigation 7.15 TRA Terminations 7.13(d) Third Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(vii) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(iiVote-Down 9.2(b)

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(bAction 3.5(g) Agreement Preamble Antitrust -12- Allocation Methodology 2.9(a) Allocation 2.9(b) Approvals 4.3(b2.10(a) Applicable Cap Amount 6.5(b)(i) Assigned Contracts 1.1(a)(iii) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) Asset Purchase Recitals Assignment Agreement and ▇▇▇▇ of Sale 1.3(b)(iii2.8(a)(v) Assumed Liabilities 2.6 Bankruptcy Code 2.13(h) Basket 7.6(a) Business Benefit Plans 2.16(aContracts 2.4(a) Business Employee 9.3(aCovered Person 5.9 Business Litigation Controlling Party 5.6(b) Buyer Preamble Buyer FDA Letters 5.3(dBusiness Litigation 5.6(a) Buyer Group 1.1(aBusiness Permits (b) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(aCap 7.6(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Closing 1.3(a7.4(c) Closing Date 1.3(a) 2.3 Closing Net Working Capital 1.4(a) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b2.3 Consent 5.12(a) Confidentiality Agreement 4.2 Contingent Payment 1.2(b5.2(a) CTAs 2.9(bControlling Party 7.4(b)(iii) Damages 6.1 DOJ 4.3(aCovered Activities 3.10(c) Domain Name Assignment Agreement 1.3(b)(viCovered Protected Information 3.10(c) Downward Adjustment Amount 1.4(c)(iDx Copyright License 2.13(a)(iii) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(aDx Framework Source Code 2.13(a)(iii) Employment Practices 2.15(bDx Infringement 2.13(f)(iv) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(aDx System License 2.13(a)(ii) Estimated Net Working Capital 1.2(eDx Test License 2.13(a)(i) Enforceability Limitations 3.2(b) Excluded Assets 1.1(b2.5 Expiration Date 7.1(a) Excluded Liabilities 1.1(dForeign Closing Documents 2.8(a)(vi) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a3.5(g) HSR Act 2.4(bHIPAA 3.5(g) Historical Financial Statements 7.4(a) Indemnified Party 6.3(a7.4(a) Indemnifying Party 6.3(a7.4(a) Inquiry 4.7(aIndependent Accounting Firm 2.9(b) IP Assignment Agreements 1.3(b)(viiContracts 3.9(i) IP Liability Assumption 7.4(b)(i) License Recitals Material Customer Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(b3.12(a) Material Contract 2.10(aCustomer Agreement 3.13(a) Material Customers 2.11 Customer 3.12(a) Material Suppliers 2.11 New Buyer Employee 9.3(aDistributor or Reseller Agreement 3.13(c) Material Distributor 3.13(c) Milestone Payment Date 2.2(c)(i) Milestone Payment 2.2(b)(i) -13- [***] Confidential Treatment Requested - Milestone Trigger 2.2(b)(i) Mutual Transfer Agreement 5.4(c) NanoString Board of Directors 3.2(a) NanoString Indemnified Parties 7.3 NanoString Indemnified Party 7.3 NanoString Other Systems 2.13(a) NanoString Preamble NIH Assignment 5.1 NIH License 5.1 NIH Outside Date 5.1 Non-Controlling Party 7.4(b)(iii) Non-Compete Period 9.9(aPaying Party 6.3(b) Non-Contingent Bonuses 9.3(cRegulatory Approvals 2.10(b) Non-Solicit Period 9.9(bTransferable Asset 2.10(a) Notice of Objection Notice 1.4(b)(i) Outside Date 7.1(d)(ii7.4(d) Parties Preamble Party Preamble Patent Assignment Agreement 1.3(b)(vPEO 5.4(c) Permits 1.1(a)(ivProduct Licenses 3.5(c) Pre-Closing Period 4.1(aPurchased Assets 2.4 Purchaser’s Allocation Notice 2.9(b) Purchaser’s Allocation 2.9(b) Registered Business IP 2.9(aLicensed Intellectual Property 3.9(a) Regulatory Authority 2.13(bPermits 5.1(a) Regulatory Filings 4.3(aRelevant Matters 8.8(a) Reimbursement Amount 9.4(cReplaced Distributor Contracts 2.10(b) Related Agreements 2.3 Restricted Names 9.5 Safety Notice Replaced Distributor Relationship 2.10(b) Replacement Distributor Contracts 2.10(b) Replacement NIH License Agreement 5.1 Retained Liabilities 2.7 Review Committee 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(aStockholders 3.2(a) Straddle Period 8.1(b)(iTax 6.3(b) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Third-Party Claim 6.3(aNotice 7.4(a) Third Third-Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(viiClaim 7.4 Transactions Recitals Transfer Claimant 5.4(d) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi6.3(a) Transferred Permits 1.1(a)(iv2.4(d) Transition Services Agreement 1.3(b)(xPeriod 2.10(b) Upfront Payment 1.2(aUnilateral Settlement 7.4(b)(iii) Upward Adjustment Amount 1.4(c)(ii)Universal Panel 2.13(a) Update Report 2.2(c)(ii) Veracyte Indemnified Parties 7.2 Veracyte Indemnified Party 7.2 Veracyte SEC Documents 4.6(a) Veracyte Preamble -14- [***] Confidential Treatment Requested -

Terms Defined Elsewhere. The following list is a list of additional capitalized terms are defined elsewhere used throughout this Agreement and a reference to the Section hereof in this Agreement, as indicated belowwhich such term is defined: 2017 Bonuses 9.3(a1374 Tax 3.10(g) Acquired Assets 1.1(a338(h)(10) Aggregate Threshold 6.5(b)(iiElection 6.9(b) Agreed Amount 6.3(b401(k) Plan 6.7(b) Actions 3.20 Agreement Preamble Antitrust Approvals 4.3(bAllocation Statement 6.9(d) Applicable Cap applicable indemnifying Persons 12.5 Articles of Merger 1.2 Audited Financial Statements 3.7 Bonus Plan 6.7(b) CFIUS 6.4(a) Closing 1.2 Closing Date 1.2 Closing Working Capital 2.4(a) Code 2.2(d) Company Preamble Company Common Stock Preamble Company Securities 3.2(b) Company Shareholders Preamble Compliance Program 6.9(k)(ii) Confidentiality Agreement 6.2 Continuing Employees 6.7(b) Damages 12.6(a) Deductible Amount 6.5(b)(i12.1(b) Assigned Contracts 1.1(a)(iiiDelaware Law Recitals Determination Date 12.1(a)(iv) Assumed Liabilities 1.1(cDisclosure Schedule 3 Dispute Notice 2.4(d) Assumption Agreements 1.1(cEffective Time 1.2 End Date 11.1(b) ERISA 3.13(a) Escrow Account 2.2(f) Escrow Agent 2.2(f) Escrow Agreement 2.2(f) Escrow Amount 2.2(f) Estimated Closing Balance Sheet 2.4(b) Estimated Working Capital 2.4(b) Estimated Working Capital Adjustment 2.4(b) Exon-▇▇▇▇▇▇ 6.4(a) Financial Statements 3.7 Foreign Benefit Plan 3.13(j) ▇▇▇▇▇▇▇▇▇ of Sale 1.3(b)(iiiPreamble Governmental Authorities 3.6 Hazardous Substance 3.21 Incentive Payments 2.3(b) Business Benefit Plans 2.16(aIncentive Plan 2.3(b) Business Employee 9.3(aIncentive Unit Holdback Amount 2.2(c)(i) Buyer Incentive Unit Payment Amount 2.3(b) Initial Calculation 2.4(c) Initial Closing Balance Sheet 2.4(c) IRS 3.13(a) Knowledge 14.8 Large Customers 3.16 Merger 1.1 Merger Consideration 2.2(a) Merger Sub Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Most Recent Balance Sheet 3.7 PCBs 3.21 Parent Preamble Parent Claim 12.4 Parent Indemnified Parties 6.1 Buyer Plans 9.3(a12.1(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Closing 1.3(a) Closing Date 1.3(a) Closing Net Working Capital 1.4(a) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b) Confidentiality Agreement 4.2 Contingent Payment 1.2(b) CTAs 2.9(b) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) Excluded Assets 1.1(b) Excluded Liabilities 1.1(d) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(b) Material Contract 2.10(a) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(a) Non-Compete Period 9.9(a) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(i) Outside Date 7.1(d)(ii) Participant Deferral Liability 6.12 Participant Release 6.12 Parties of Interest Preamble Party of Interest Preamble Patent Assignment Agreement 1.3(b)(vPayment Instructions 2.2(b) Permits 1.1(a)(iv3.22(b) Phantom Stock Holdback Amount 2.2(c)(ii) Phantom Stock Payment Amount 2.3(c) Phantom Stock Payments 2.3(c) Phantom Stock Plans 2.3(c) Plan 3.13(a) Pre-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(cIncome Tax Returns 6.9(j) Related Agreements 2.3 Restricted Names 9.5 Safety Party 6.1(u) Representative Preamble Required Consents 6.4(b) Rhode Island Law Recitals RIBCA 1.1 Section 338 Forms 6.9(c) Securities Act 3.4 Seller Expenses 2.3(a) Settlement Accountants 2.4(d) Settlement Notice 2.13(d2.4(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(a) Shareholders Agreement 4.3 Straddle Period 8.1(b)(i12.1(a)(iv) Sublease 1.3(b)(xiSubsidiary Securities 3.3(a) Supply Agreements 4.6 Supplemental Indemnity Amount 12.2(b) Surviving Corporation 1.1 Tax Claim 8.4 Indemnified Party 6.9(l)(i) Tax Indemnifying Party 6.9(l)(i) Tax Proceedings 6.9(k)(i) Tax Purchase Price 6.9(d) Third Party Claim 6.3(a) Third Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(vii) 12.5 Transfer Taxes 8.1(a6.9(f) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(iiUnaudited Financial Statements 3.7 Working Capital 2.4(a)

Terms Defined Elsewhere. The In addition to the terms defined in Section 1.1, each of the following terms are is defined elsewhere in this Agreement, as indicated the Section of the Agreement set forth opposite such term below: 2017 Bonuses 9.3(aAccounting Rules 5.6(b) Acquired Assets 1.1(aADSP 8.7(g) Aggregate Threshold 6.5(b)(iiAllocation Schedule 8.7(g) Agreed Amount 6.3(bArticles of Merger 2.2 Audited Buyer Financials 7.5(a) Audited Company Financials 5.6(a) Auditor 3.3(d)(i) Bank 5.1(a) Bank Merger 2.7 Bank Merger Agreement Preamble Antitrust Approvals 4.3(b2.7 Bankruptcy and Equity Exceptions 5.2 Basket 10.6(a)(i) Applicable Cap Amount 6.5(b)(iBOLI 2.8(a)(ii)(C) Assigned Contracts 1.1(a)(iii) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) ▇▇▇▇ of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee 9.3(aBranch Leases 5.12(a)(i) Buyer Preamble Buyer FDA Letters 5.3(dAppraisal Delivery Date 3.4(a) Buyer Group 1.1(aCovered Losses 10.6(a)(i) Buyer Indemnified Parties 6.1 Disclosure Schedule Preamble to Article 7 Buyer Indemnitee 10.1 Buyer Losses 10.1 Buyer Plans 9.3(a8.6(b) Cap 10.6(a)(iii) Certificate 2.6(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) 10.3 Closed Branches 8.17 Closing 1.3(a) 4.1 Closing Date 1.3(a4.1 Closing Payment 3.1(a) Closing Net Working Capital 1.4(aCommon Interest Information 8.22(c) Closing Statement 1.4(aCompany Preamble Company Appraisal Delivery Date 3.4(c) COBRA 9.3(fCompany Disclosure Schedule Preamble to Article 5 Company Financials 5.6(a) Commercial Business Introduction Commercial Business Company Plans 5.18(a) Company Stock Recitals Damages 10.1 Derivative Transactions 5.13 Disclosure Schedule 8.11 Dispute Notice 3.3(b) Disputed Matters 3.3(b) Effective Time 2.2 Environmental Laws 5.17 Environmental Survey 8.21(a) ESOP 5.18(e) Estimated Effective Time Balance Sheet Date 2.5(b3.2 FBCA Recitals FHLBA 5.1 Final Losses 10.4(e) Confidentiality Agreement 4.2 Contingent Payment 1.2(bFinal Net Book Value 3.3(e) CTAs 2.9(bFirst Negotiation Period 3.4(b) Damages 6.1 DOJ 4.3(aFiserv Contract 2.8(a)(ii)(H) Domain Name Assignment Agreement 1.3(b)(viFraud 10.6(a) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) Excluded Assets 1.1(b) Excluded Liabilities FRB 1.1(d) FDA 2.13(bFTMC 5.1(a) Final Allocation 8.5 Final Net Working Capital 1.4(b)(ivFTST 5.1(a) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(bIncumbent Counsel 8.14(a) Indemnified Party 6.3(a) 10.3 Indemnifying Party 6.3(a10.3 Interim Company Financials 5.6(a) Inquiry 4.7(aIRS 5.18(c) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(bLien 5.3 Losses 10.6(b) Material Contract 2.10(aContracts 5.12(b) Material Customers 2.11 Defect 8.21(d) Material Suppliers 2.11 New Buyer Employee 9.3(aDefect Notice 8.21(c) Merger Recitals Merger Consideration 3.1(a) Monthly Financials 8.19 Negative True-Up Amount 3.3(e)(ii) Net Book Value 2.8(b) Non-Compete Period 9.9(aContinuing Employee 8.6(a) Non-Contingent Bonuses 9.3(cPerforming 2.10(b) Non-Solicit Period 9.9(bOCC 1.1(d) Objection Notice 1.4(b)(iOrder 5.8 Other Transferred Assets 2.9 Outside Closing Date 11.1(b)(ii) Outside Date 7.1(d)(iiOwned Branch Property 5.16 Parent Preamble Parent Covered Losses 10.6(a)(ii) Parent Disclosure Schedule Preamble to Article 6 Parent Indemnitee 10.2 Parent Losses 10.2 Parties Preamble Party Preamble Patent Assignment Agreement 1.3(b)(vPermits 5.9 Permitted Real Estate Liens and Exceptions 5.16 Plaintiff Litigation 8.22(a) Permits 1.1(a)(ivPolicies 5.18 Pool 5.11(g) PrePositive True-Closing Up Amount 3.3(e)(i) Property Examination 8.21(a) Property Review Appraisal Factors 8.21(c) Property Review Period 4.1(a8.21(a) Registered Business IP 2.9(aPut Date 8.16(c) Put Notice 8.16(c) Put Period 8.16(a) Qualified MAI Appraiser 3.4(a) Regulatory Authority 2.13(bApproval 9.1(c) Regulatory Filings 4.3(aRepresentatives 8.3(a) Reimbursement Amount 9.4(cRepurchase Price 8.16(g) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(dRepurchased Loan 8.16(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(aResponse Period 10.4(a) Seller Disclosure Letter Article II Seller FDA Letters 5.2(gRevised Effective Time Balance Sheet 3.3(a) Seller FSA 9.3(aSecond Negotiation Period 3.4(d) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(vSection 338(h)(10) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(iElection 8.7(f) Seller Trademarks 9.6 Shire Milestone Payment 9.4(aServicing Agreement 4.2(e) Specified Milestone Payment 9.4(a) Straddle Period 8.1(b)(i) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Shares 2.6 Third Party Claim 6.3(aAppraiser 3.4(e) Third Party IP 2.9(bAction 10.4(a) Trademark Assignment Agreement 1.3(b)(viiThird Party Action Notice 10.4(a) Transfer Taxes 8.1(aTransaction Documents 5.2 Transferred Assets 2.8(a)(ii) Transferred Accounts Receivable 1.1(a)(xivBranch Lease 2.8(a)(ii)(D) Transferred Inventory 1.1(a)(xiHolding Company Assets 2.8(a)(i) Transferred IP 1.1(a)(ivLoans 2.8(a)(ii)(B) Transferred IP Agreements 2.9(bPersonal Property 2.8(a)(ii)(F) Transferred IP Documentation 1.1(a)(viOwned Branch Property 2.8(a)(ii)(E) Transferred Permits 1.1(a)(ivEmployees 8.6(b) Transition Services Agreement 1.3(b)(xTransferred Loans 2.10(a) Upfront Payment 1.2(aTransferred Records 8.4 Transitional Employees 8.6(a) Upward Adjustment Amount 1.4(c)(ii)TruPS 2.8(a)(i)(A) TruPS Assumption 8.15 USA PATRIOT Act 5.9

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: 2017 Bonuses 9.3(aTerm Section Adjustment Excess Amount 2.4(d) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Adjustment Shortfall Amount 6.3(b2.4(d) Agreement Preamble Antitrust Approvals 4.3(bAllocation Dispute 1.5(a) Applicable Cap Amount 6.5(b)(iAllocation Dispute Notice 1.5(a) Assigned Allocation Resolution Period 1.5(a) Approval Motion 5.7(a) Approval Order 5.7(a)(i) Arbitrator 2.4(b) Assignment and Assumption Agreement 1.3(b) Assumed Contracts 1.1(a)(iii1.1(a)(vi) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(cAssumed Real Property Leases 1.1(a)(x) Bankruptcy and Equity Exception 3.3 Bankruptcy Cases Recitals Bankruptcy Code Recitals Bankruptcy Court Recitals Bankruptcy Court Orders 5.7(a)(ii) Benefit Plan 3.11I Bidding Procedures 5.7(a)(ii) Bidding Procedures Order 5.7(a)(ii) ▇▇▇▇ of Sale 1.3(b)(iii2.2(a)(i) Books and Records 5.3(b)(i) Break-Up Fee 7.5(b)(ii) Business Benefit Plans 2.16(a) Business Employee 9.3(a) Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Recitals Closing 1.3(a) 2.1 Closing Date 1.3(a2.1 Code 1.5(a) Closing Net Working Capital 1.4(aConsent Asset 1.3(c) Closing Statement 1.4(aConditional Approval Order 7.4(f) COBRA 9.3(fD&O Insurance 5.6(a) Commercial Business DinoKing Assumed Liabilities 1.1(c)(iv) DinoKing Insolvency Proceeding Cost 5.18(d) DinoKing Proceeding 5.18 Disclosure Letters Introduction Commercial Business Balance Sheet Date 2.5(bto Article IV Dispute 1.5(b) Confidentiality Agreement 4.2 Contingent Payment 1.2(bEscrow Amount 2.3(b) CTAs 2.9(b) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(aEscrow Funds 2.3(b) Estimated Net Working Capital 1.2(eCurrent Assets 2.3(b) Estimated Current Asset Statement 2.3(b) ERISA 3.11(c) Excluded Assets 1.1(b) Excluded Liabilities 1.1(d) FDA 2.13(bContracts Recitals Final Allocation Schedule 1.5(a) Final Allocation 8.5 Final Net Working Capital 1.4(b)(ivCurrent Assets 2.4(c) FSA Balances 9.3(aFinancial Statements 3.5(a) FSA Participants 9.3(aGood Faith Deposit 1.4(a) FTC 4.3(aInsurance Policies 5.1(b)(xi) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(bInterim Period 5.1(a) Material Contract 2.10(a3.10 Notice of Objection 2.4(a) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(a) Non-Compete Period 9.9(a) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(iOwned Real Property 3.12(a) Outside Date 7.1(d)(ii7.4(j) PacBridge Parties Preamble Party Preamble Patent Assignment Agreement 1.3(b)(vSettlement 5.7(h) Permits 1.1(a)(iv3.8(b) Pre-Closing Period 4.1(aProposed Allocation Schedule 1.5(a) Purchaser Preamble Purchaser Default Termination 1.4(b)(ii) Purchaser Disclosure Letter Introduction to Article IV Real Property 3.12(a) Real Property Lease Assignments 2.2(a)(iii) Real Property Leases 3.12(a) Registered Business IP 2.9(aIntellectual Property 3.14(a) Regulatory Authority 2.13(bReview Period 2.4(a) Regulatory Filings 4.3(aRMST Shares 3.2(b) Reimbursement Amount 9.4(cRMST Securities 3.2(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(dSection 338(h)(10) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(aElection 5.10(d) Seller Disclosure Letter Introduction to Article II III Seller FDA Letters 5.2(gEmployees 5.5(b) Seller FSA 9.3(aSellers Preamble Service Provider 3.11(c) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(a) Straddle Period 8.1(b)(i) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Party Claim 6.3(a) Third Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(vii) Transfer Taxes 8.1(aTitle Insurance Policy 5.16(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(iiEmployees 5.5(a)